Viral Hepatitis Registry, Kaiser Permanente Division of Research, Oakland, CA, USA,
Dig Dis Sci. 2014 Sep;59(9):2100-8. doi: 10.1007/s10620-014-3142-2. Epub 2014 Apr 12.
Few population-based studies have described characteristics and management of patients with chronic hepatitis B (CHB) in the USA.
We retrospectively studied adults with CHB in the Northern California Kaiser Permanente Medical Care Program (KPNC) from July 2009 to December 2010 (n = 12,016). Laboratory tests, treatment patterns, and hepatocellular carcinoma (HCC) surveillance were ascertained during a "recent" 18-month study window (July 2009-December 2010), or as "ever" based on records dating to 1995.
The mean age was 49 years; 51 % were men, 83 % Asian, and 87 % KPNC members >5 years. Overall, 51 % had ≥ 1 liver-related visit, 14 % with gastroenterology or infectious disease specialists, and 37 % with primary care providers (PCP) only. Less than 40 % of patients had both hepatitis B virus (HBV) DNA and ALT testing conducted recently, while 56 % of eligible patients had received HCC surveillance. Recent laboratory testing and HCC surveillance were more frequent in patients seen by a specialist versus PCP only (90 vs. 47 % and 92 vs. 73 %, respectively, p values <0.001). During the study period, 1,649 (14 %) received HBV treatment, while 5 % of untreated patients had evidence of treatment eligibility. Among 599 patients newly initiated on HBV therapy, 76 % had guideline-based indications for treatment.
Most patients initiated on HBV treatment met eligibility, and very few patients with evidence of needing treatment were left untreated. However, monitoring of ALT and HBV DNA levels, as well as HCC surveillance, were not frequent, underestimating the proportion of patients that warranted HBV therapy. Viral monitoring and cancer surveillance are therefore important targets for improving the scope of CHB care in the community setting.
很少有基于人群的研究描述过美国慢性乙型肝炎(CHB)患者的特征和管理情况。
我们对 2009 年 7 月至 2010 年 12 月期间北加州凯撒永久医疗保健计划(KPNC)的成年 CHB 患者进行了回顾性研究(n=12016)。实验室检测、治疗模式和肝细胞癌(HCC)监测是在最近的 18 个月研究窗口(2009 年 7 月至 2010 年 12 月)期间确定的,或者根据 1995 年以来的记录确定为“既往”。
平均年龄为 49 岁;51%为男性,83%为亚洲人,87%为 KPNC 成员>5 年。总体而言,51%的患者有≥1次肝脏相关就诊,14%的患者就诊于胃肠病学或传染病专家,37%的患者仅就诊于初级保健提供者(PCP)。最近进行了乙型肝炎病毒(HBV)DNA 和 ALT 检测的患者不到 40%,而符合条件的患者中有 56%接受了 HCC 监测。与仅接受 PCP 治疗的患者相比,接受专科医生治疗的患者最近进行实验室检测和 HCC 监测的频率更高(分别为 90%和 92%比 47%和 73%,p 值均<0.001)。在研究期间,1649 名(14%)患者接受了 HBV 治疗,而未接受治疗的患者中有 5%有治疗资格。在新开始接受 HBV 治疗的 599 名患者中,76%的患者有基于指南的治疗指征。
大多数开始接受 HBV 治疗的患者符合治疗条件,很少有有治疗需要的患者未接受治疗。然而,ALT 和 HBV DNA 水平的监测以及 HCC 监测并不频繁,这低估了需要 HBV 治疗的患者比例。因此,病毒监测和癌症监测是改善社区环境中 CHB 治疗范围的重要目标。